Active Ingredient(s): Calcifediol
FDA Approved: * June 17, 2016
Category: Osteoporosis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Rayaldee Overview

Calcifediol, also known as calcidiol, 25-hydroxycholecalciferol, or 25-hydroxyvitamin D3 (abbreviated 25(OH)D3),[1] is a form of vitamin D produced in the liver by hydroxylation of vitamin D3 (cholecalciferol) by the enzyme vitamin D 25-hydroxylase.[2][3] Calcifediol can be further hydroxylated by the enzyme 25(OH)D-1α-hydroxylase, primarily in the kidney, to form calcitriol (1,25-(OH)2D3), which is the active hormonal form of vitamin D.&a...

Read more Rayaldee Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Calcifediol

Recent Rayaldee Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 0.02mg, 0.05mg, 20mcg
  • Capsule, Extended Release: 0.03mg, 30mcg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Rayaldee: (1 result)

Sorted by National Drug Code
  • 70301-1001 Rayaldee 30 ug/1 Oral Capsule, Extended Release by Opko Pharmaceuticals LLC

Other drugs which contain Calcifediol or a similar ingredient: (2 results)